Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is launching the new VisioNize® box 2,
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Alembic Pharmaceutica
Since it’s an ingredient in so many foods, you h
Dear Readers,Welcome to the latest issue of Microb
AstraZeneca and Oxford University’s COVID-19 vaccine has similar efficacy against the British coronavirus version as it does to the previously circulating variants, the university said on Friday.
The version, first identified in Kent, southern England, is more readily transmissible, prompting many countries to limit travel to Britain. It also led to a spike in infections that forced a new national lockdown in England last month.
This lockdown came as Britain started rolling out the AstraZeneca vaccine. Over 10 million people have received a first dose of either AstraZeneca or Pfizer’s shot.
Britain had said that it considered the vaccines were effective against variants which are circulating in the united kingdom.
“Data from our trials of this ChAdOx1 vaccine in the United Kingdom indicate that the vaccine not only protects against the initial pandemic virus, but also protects against the publication variant, B.1.1.7, which caused the surge in disease in the end of 2020 across the united kingdom,” explained Andrew Pollard, Chief Investigator on the Oxford vaccine trial.
Sarah Gilbert, co-developer of this vaccine, said that, although the vaccine had efficacy against the UK variant, it may need to be accommodated for a future version.
“We are working with AstraZeneca to optimise the pipeline necessary for a strain change should one become necessary,” Gilbert said.
The findings, published in a preprint paper and not peer-reviewed, also detailed recent study showing that vaccination with the shot causes a decrease in the duration of shedding and viral load, which might translate into a reduced transmission of the disease, Oxford University said.
